Quality by Design in API Manufacturing
Speakers
Lígia Brás, Hovione, Portugal
Hiltrud Horn, Horn Pharmaceutical Consulting, Germany
Francois Vandeweyer, Janssen Pharmaceutica, Belgium
Elmar Wenzel, Freelance Consultant, Germany
Objectives
During this course the principles and key aspects of Quality by Design will be discussed. You will learn
- How to identify Critical Quality Attributes
- How to design an effective risk based control strategy
- How to provide QbD related information in a regulatory submission
- How Process Analytical Technology can be applied as part of a control strategy
Background
In many cases the synthesis of small molecule APIs is achieved by using multiple intermediates which themselves are produced using different processes. To ensure the API manufacturing process consistently delivers an API meeting its specifications each of these processes needs to be robust.
The Quality by Design approach aims to scientifically determine product and process characteristics derived from criteria set after analysis of the intended drug application.
These product characteristics, the so called critical quality attributes (CQAs), must be identified and in the next step the critical process parameters (CPPs) have to be
determined.
Suitable approaches to identify these parameters are design of experiments (DOE) or general risk assessments e.g. FMEA. When linked to each other the CQAs and CPPs define the range within the process is considered to be robust.
This has to be demonstrated by a compilation of the relevant information in the application dossier.
Target Group
This course is designed for all persons which are
involved in the manufacture of APIs especially in process development, process validation, scale-up and transfer and CMC dossier preparation. Furthermore, the seminar will be of interest to personnel from quality assurance, regulatory affairs both from API and pharmaceutical companies and to contract manufacturers.
Programme
General framework and key elements of QbD for APIs – background and potential strategies
- What is it all about?
- What are the benefits?
- When and how should you use it?
- Practical examples with typical points of discussion
- Severity assessment of quality attributes
- Impact levels for critical process parameters (CPPs) and critical material attributes (CMAs)
- Considerations for the API Starting material
- Design of an effective risk-based control strategy
- Examples
- What should be done at which stage?
- Which information is relevant for the dossier?
- What are the key-points to be considered for APIs (NCE/Biotech) and their formulations
- Typical questions from Authorities
- Changing Validation Approach
- Validation Life Cycle
- Design Space Concept
- PAT at development stages of a QbD-based development
- PAT as part of the Control Strategy in a GMP environment
- Practical examples of PAT implementations at a commercial scale in a GMP environmen
Control strategies – Case studies and examples
- HA definitions
- Why and When is a control strategy needed
- Different types/elements of a control strategy
- Practical examples
In this workshop delegates will elaborate criticality analyses of different APIs. As part of this analyses critical quality attributes and critical process steps within the synthesis of the APIs will be identified.
This course is part of the GMP Certification Programme "ECA Certified Pharmaceutical Development Manager" Learn more
This training/webinar cannot be booked. Send us your inquiry by using the following contact form.
To find alternative dates for this training/webinar or similar events please see the complete list of all events.
For many training courses and webinars, there are also recordings you can order and watch any time. Just take a look at the complete list of all recordings.
Not available
Not available
Not available
Please contact us:
Tel.: +49 6221 8444-0
E-Mail: info@gmp-compliance.org
- Our Service
Testimonials- Your Certificate
Seminar Programme as PDF
